Chicago, IL – June 16, 2025 – Zacks.com releases the list of companies likely to issue earnings surprises. This week’s list ...

QIAGEN N.V. QGEN recently announced a new global collaboration with Incyte INCY. The partnership enhances QIAGEN’s onco-hematology diagnostics pipeline and supports Incyte’s extensive portfolio in ...

Investing in today’s dynamic market requires a keen eye for value, and Hims & Hers Health, Inc. ($HIMS) has been catching attention with its explosive ...

Hassan: Two private security personnel and a police constable allegedly assaulted an unknown man for 30 minutes at Hassan ...

Discover why Hims & Hers is leading the telehealth market with strong growth, a loyal user base, and expansion into new ...

Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Eli Lilly found itself in a pharmaceutical pickle after its CFO claimed telehealth partners don’t compound key weight-loss ...

HWM surges on aerospace demand, rising earnings, and upgraded guidance, while SQM stumbles on weak results and estimate cuts.

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...